Poll Shows Only 6% Report Major Side Effects After COVID Vaccination

Only 6% of vaccinated candidates reported severe side-effects or sickness after being administered the COVID vaccines, revealed poll results.

The IANS C-Voter Covid tracker also found 33.6 per cent respondents reported little //side-effects or sick, while 57.2 per cent had no side-effects or fall ill after the vaccine doses.

COVID-19 Vaccination in India: Issues and Challenges
India’s COVID-19 vaccination program has been launched. It currently uses the vaccines Covishield and Covaxin. There are some issues and challenges that need to be overcome in order to vaccinate all Indians.

‘44.6% respondents received doses of Covishield and 23.3% percent received Covaxin. ’

About 3.2 per cent respondents said that they did not know or couldn't say whether they felt any side-effects or got sick after getting vaccinated.

About 32.2 per cent respondents did not know which Covid vaccine shots they got.

About 56,685 respondents were surveyed from January 1 to May 27 this years.

Covaxin Shot Can Hamper Travel Plans of Indians
Indians who received Bharat Biotech's Covid-19 vaccine 'Covaxin jabs' may not qualify for travelling abroad. Covaxin is not yet on the World Health Organization's (WHO) Emergency Use Listing (EUL).

This survey is based on CATI interviews of adult (aged over 18) respondents across all segments covering all 542 Lok Sabha segments. Margin of error is plus minus three per cent at State level and plus minus five per cent at regional level. Data weighted to the known Census profile, including Gender, Age, Education, Rural or Urban, Religion and Caste apart from the voting recalls for last Lok Sabha and Vidhan Sabha elections.

Source-IANS

Covaxin Offers Protection Against New COVID-19 Variants
Bharat Biotech's Covaxin demonstrates protection against the new Covid-19 variants, says new study. A modest reduction in neutralisation was observed against B1617 variant compared to vaccine variant.

India's First COVID-19 Vaccine, Covishield Roll Out in Coming Weeks
Covishield, India's first coronavirus vaccine will roll out in the coming weeks, said Adar Poonawalla, CEO, Serum Institute of India (SII).